hit counter
Athenex, Inc. (ATNX) Stock News Sentiment & Price - Sentifly
ATNX - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Athenex, Inc. (ATNX)

USA
Biotechnology
NASDAQ
ATNX Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ATNX Latest news
GlobeNewsWire
Neutral
Athenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Cell Therapy
2021-10-18 08:15

Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR)

Zacks Investment Research
Negative
After Plunging 25.6% in 4 Weeks, Here's Why the Trend Might Reverse for Athenex (ATNX)
2021-10-12 13:23

Athenex (ATNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

GlobeNewsWire
Neutral
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer
2021-10-11 08:00

BUFFALO, N.Y., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently held a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for oral paclitaxel and encequidar (Oral Paclitaxel) in metastatic breast cancer (mBC). The purpose of the meeting was to review with the FDA a proposed design for a new clinical trial intended to address the deficiencies raised in the Complete Response Letter received in February 2021 and discuss the potential regulatory path forward for Oral Paclitaxel in mBC in the U.S.

PennyStocks
Positive
5 Penny Stocks To Buy According To Insiders In September
2021-09-16 13:31

Insiders are buying shares of these penny stocks this months; are you? The post 5 Penny Stocks To Buy According To Insiders In September appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Benzinga
Positive
Athenex Shares Are Trading Higher On Positive Oral Paclitaxel Data From Solid Tumor Trial
2021-09-16 08:04

Athenex Inc (NASDAQ: ATNX) announced data presentation from a Phase 1 study evaluating encequidar (Oral Paclitaxel) in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in advanced solid malignancies. Paclitaxel is one of the most commonly used chemotherapies.

GlobeNewsWire
Neutral
Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021
2021-09-16 02:30

Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging anti-tumor activity (4 PR out of 8 evaluable patients) in NSCLC patients who failed prior PD1/PDL1 therapies Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging anti-tumor activity (4 PR out of 8 evaluable patients) in NSCLC patients who failed prior PD1/PDL1 therapies

GlobeNewsWire
Neutral
Athenex to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & Med Tech Summit
2021-09-15 08:00

BUFFALO, N.Y., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board Chairman, and Daniel Lang, Senior Director, Corporate Development will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Wednesday, September 22, 2021 at 10:45 a.m. ET.

Seeking Alpha
Neutral
Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.
2021-08-31 17:19

Athenex, Inc. is a biopharmaceutical company developing and commercializing next-generation drugs for treating various cancers. Athenex's pipeline consists of four therapeutic programs, Orascovery (P-glycoprotein pump inhibitor), Src Kinase Inhibition, Cell Therapy, and Arginine Deprivation Therapy.

Seeking Alpha
Neutral
Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2021 Results - Earnings Call Transcript
2021-08-07 18:21

Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2021 Results - Earnings Call Transcript

Zacks Investment Research
Negative
Athenex (ATNX) Reports Q2 Loss, Misses Revenue Estimates
2021-08-05 09:54

Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and -0.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Loading more news...